SLC27A2 participates in the immune process of hematological tumors through T cell CD8 + and macrophages, In DLBCL, patients with low expression of SLC27A2 have poorer prognosis, while in AML, patients with high expression of SLC27A2 have poorer prognosis (Fig. S4). Here, SLC27A2 is linked to acute myeloid leukemia.